Restricted accessReview articleFirst published online 2023-6
Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials
To investigate whether dexmedetomidine (DEX), as adjunctive therapy to benzodiazepine (BZD), is superior to BZD alone in critically ill patients with alcohol withdrawal syndrome (AWS).
Data Sources:
PubMed Central, Cochrane CENTRAL, ClinicalTrials.gov and Google Scholar were used as search databases. Specific keywords and MeSH terms were “dexmedetomidine,” “benzodiazepine,” and “alcohol withdrawal syndrome.” The last search was on September 16, 2022.
Study Selection and Data Extraction:
Randomized controlled trials (RCTs) and nonrandomized/cohort studies exploring the use of DEX in the management of AWS were included. A total of 12 studies were included in the systematic review and 7 in the meta-analysis.
Data Synthesis:
The intensive care unit length of stay (ICU LOS) was found to have a mean difference (MD) of 48.06 [37.48, 58.64], P = <0.001 for the cohort subgroup, significantly favoring the DEX arm, but, in contrast, pooled RCT data showed a result of –20.07 [–36.86, –3.28], P = 0.02, a shorter ICU LOS for the DEX arm. Bradycardia and hypotension incidence significantly favored the BZD arm in both subgroups. This study compares the effectiveness of adjunctive DEX in clinical practice and aims to help providers in critical decision-making by compiling and analyzing the best current available evidence of its use in AWS.
Conclusions:
Based on low to very low level of evidence, adjunctive DEX showed no significant difference for ICU LOS when compared with BZD alone. Pooled randomized trials potentially show a benefit but are similarly limited by their low quality of evidence.
GoodsonCMClarkBJDouglasIS. Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcohol Clin Exp Res. 2014;38(10):2664-2677. doi:10.1111/acer.12529.
3.
SalottoloKMcGuireEMainsCWvan DoornECBar-OrD. Occurrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens following traumatic injury. Crit Care Med. 2017;45(5):867-874. doi:10.1097/CCM.0000000000002371.
TsaiGGastfriendDRCoyleJT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152(3):332-340. doi:10.1176/ajp.152.3.332.
6.
MorrowALSuzdakPDKaranianJWPaulSM. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl-uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther. 1988;246(1):158-164.
7.
SchuckitMA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109-2113. doi:10.1056/NEJMra1407298.
8.
Mayo-SmithMFBeecherLHFischerTL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. [published correction appears in Arch Intern Med. 2004;164(18):2068] Arch Intern Med. 2004;164(13):1405-1412. doi:10.1001/archinte.164.13.1405.
9.
WangSHChenWSTangSE, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2019;9:1513. doi:10.3389/fphar.2018.01513.
10.
FukasawaTSuzukiAOtaniK. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32(4):333-341. doi:10.1111/j.1365-2710.2007.00829.x.
11.
CagettiELiangJSpigelmanIOlsenRW. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol. 2003;63(1):53-64.
12.
LangloisHCormierMVilleneuveEHoffmanRSLongoCGosselinS. Benzodiazepine resistant alcohol withdrawal: what is the clinician’s preferred definition?CJEM. 2020;22(2):165-169. doi:10.1017/cem.2019.421.
13.
DixitDEndicottJBurryL, et al. Management of acute alcohol withdrawal syndrome in critically ill patients. Pharmacotherapy. 2016;36(7):797-822. doi:10.1002/phar.1770.
WoodsADGiomettiRWeeksSM. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database System Rev Implement Rep. 2015;13(1):224-252. doi:10.11124/jbisrir-2015-1602.
16.
GlahnAProskynitopoulosPJBleichSHillemacherT. Pharmacotherapeutic management of acute alcohol withdrawal syndrome in critically Ill patients. Expert Opin Pharmacother. 2020;21(9):1083-1092. doi:10.1080/14656566.2020.1746271.
17.
BegMFisherSSiuDRajanSTroxellLLiuVX. Treatment of alcohol withdrawal syndrome with and without dexmedetomidine. Perm J. 2016;20(2):49-53. doi:10.7812/TPP/15-113.
18.
CrispoALDaleyMJPepinJLHarfordPHBrownCV. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines. Pharmacotherapy. 2014;34(9):910-917. doi:10.1002/phar.1448.
19.
GuyattGOxmanADAklEA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026.
20.
RosnerB. Chapter 7: Hypothesis testing: categorical data/estimation of sample size and power for comparing two binomial proportions. In: Taylor M, Seibert D, Walsh S, eds. Fundamentals of Biostatistics. 7th ed.Brooks/Cole, Boston; 2011: 381-389.
21.
PaezA. Gray literature: an important resource in systematic reviews. J Evid Based Med. 2017;10(3):233-240. doi:10.1111/jebm.12266.
22.
LoCKMertzDLoebM. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45. doi:10.1186/1471-2288-14-45.
23.
HigginsJPTSallyGreen. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). London, England: Cochrane Group; 2011. Accessed September 26, 2022. https://handbook-5-1.cochrane.org/front_page.htm.
24.
LuoDWanXLiuJTongT. Optimally estimating the sample mean from the sample size, median, mid-range and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785-1805.
25.
ShiJLuoDWengH, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641-654.
26.
Review Manager (RevMan) [Computer program], Version 5.4. London, England: The Cochrane Collaboration; 2020.
27.
StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.
28.
ShiJLuoDWanX, et al. Detecting the skewness of data from the sample size and the five-number summary. arXiv preprint arXiv:2010.05749.
29.
LizotteRJKappesJABartelBJHayesKMLesselyoungVL. Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal. Clin Pharmacol. 2014;6:171-177. doi:10.2147/CPAA.S70490.
30.
TerraLThomasS. 821: Effect of dexmedetomidine on ICU length of stay in the setting of severe alcohol withdrawal. Crit Care Med. 2020;48(1):390.
LoveKZimmermannAE. Use of propofol plus dexmedetomidine in patients experiencing severe alcohol withdrawal in the intensive care unit. J Clin Pharmacol. 2020;60(4):439-443. doi:10.1002/jcph.1539.
34.
CollierTEFarrellLBKillianADKatariaVK. Effect of adjunctive dexmedetomidine in the treatment of alcohol withdrawal compared to benzodiazepine symptom-triggered therapy in critically ill patients: the EvADE study. J Pharm Pract. 2022;35(3):356-362. doi:10.1177/0897190020977755.
35.
YavarovichERBintvihokMMcCartyJCBreezeJLLaCameraP. Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay. J Intensive Care. 2019;7:49. doi:10.1186/s40560-019-0405-1.
36.
VanderWeideLAFosterCJMacLarenRKiserTHFishDNMuellerSW. Evaluation of early dexmedetomidine addition to the standard of care for severe alcohol withdrawal in the ICU: a retrospective controlled cohort study. J Intensive Care Med. 2016;31(3):198-204. doi:10.1177/0885066614554908.
37.
BielkaKKuchynIGlumcherF. Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study. Ann Intensive Care. 2015;5(1):33. doi:10.1186/s13613-015-0075-7.
38.
MuellerSWPreslaskiCRKiserTH, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014;42(5):1131-1139. doi:10.1097/CCM.0000000000000141.
39.
RovasaloATohmoHAantaaRKettunenEPalojokiR. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006;28(4):362-363. doi:10.1016/j.genhosppsych.2006.03.002.
40.
DarroujJPuriNPrinceELomonacoASpevetzAGerberDR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42(11):1703-1705. doi:10.1345/aph.1K678.
41.
LinnDDLoeserKC. Dexmedetomidine for alcohol withdrawal syndrome. Ann Pharmacother. 2015;49(12):1336-1342. doi:10.1177/1060028015607038.
42.
RaynerSGWeinertCRPengHJepsenS, Broccard AF; Study Institution. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(1):12. doi:10.1186/2110-5820-2-12.
43.
FrazeeENPersonettHALeungJGNelsonSDierkhisingRABauerPR. Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care. 2014;29(2):298-302. doi:10.1016/j.jcrc.2013.11.016.
44.
SingalAGHigginsPDWaljeeAK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45. doi:10.1038/ctg.2013.13.
45.
KaurMSinghPM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res. 2011;5(2):128-133. doi:10.4103/0259-1162.94750.
46.
Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
